Symbollon Pharmaceuticals Announces Agreement With Integra Labs, Inc. for Distribution of IoGen(TM)

• Press Release
• Source: Symbollon Pharmaceuticals, Inc.
• On 12:44 pm EDT, Tuesday July 7, 2009

FRAMINGHAM, MA--(Marketwire - 07/07/09) - Symbollon Pharmaceuticals, Inc. (OTC.BB:SYMBA - News) announces the company has entered into a distribution agreement with Integra Labs, Inc. for the distribution of their breast health formulation IoGen(TM).

Related Quotes

Symbol	Price	Change
SYMBA.OB	0.03	0.00

{"s" : "symba.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

On June 30, 2009, Symbollon Pharmaceuticals, Inc. signed a distribution agreement with Integra Labs, Inc. granting Integra the exclusive right to distribute Symbollon's dietary supplement, IoGen(TM), in countries allowing over-the-counter sales of the product. Under the agreement, Integra will assume all manufacturing, sales and marketing responsibilities for the product. In addition, Integra will purchase Symbollon's existing inventory of IoGen(TM). Integra will pay Symbollon a royalty on all sales of IoGen. The initial term of the agreement is for five years, subject to the achievement of certain milestones and minimum sales requirements. Pursuant to the agreement, the parties intend to identify other OTC product opportunities utilizing Symbollon's molecular iodine technology which would also be distributed by Integra.

"We are very excited to have joined forces with Integra to expand the market for IoGen(TM)," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "We are confident Integra's sales and marketing acumen will help to substantially increase the sales of IoGen(TM). We look forward to developing with Integra other OTC products based on the company's molecular iodine technology which will target other significant market opportunities."

Martha Herrod, President of Integra Labs, Inc., stated that "We are proud to be the exclusive distributor of IoGen(TM) and are anxious to start generating sales. Our existing strategic relationships and experienced sales force intend to market IoGen(TM) to success. We also look forward to several potential joint ventures in the future."

About Symbollon Pharmaceuticals, Inc.

Symbollon Pharmaceuticals, Inc. (OTC.BB:SYMBA - News) is a specialty pharmaceutical company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobial uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.

About Integra Labs, Inc.

Integra Labs, Inc. is an online marketing and media company engaged in the promotion of alternative health remedies and other healthy living solutions. Integra partners with life science based companies to develop, produce and market products backed by science and efficacy catering to market segments that provide a net positive benefit with a long-term customer lifecycle. Integra's marketing activities are primarily in the $5 billion direct-to-consumer supplement sales via the World Wide Web, targeted towards active consumers between the ages of 18 and 55. Integra believes that the quality of its products and effectiveness of its marketing network are the strengths behind its success. For more information go to: www.Integralabs.com.

Forward-Looking Statement

This news release contains statements by Symbollon that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to increase sales of IoGen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) Symbollon will be able to enter into new strategic alternatives, including sale of the Company or its assets, (iv) management and the Board of Directors will be able to maximize shareholder value by leveraging Symbollon's proprietary technology, and (v) such other factors as may be disclosed from time-to-time in Symbollon's reports as filed with the Securities and Exchange Commission.

 
Contact:
Paul C. Desjourdy
President and CEO
Symbollon Pharmaceuticals, Inc.
(508) 620-7676, x202
http://www.symbollon.com
Heather Kerwin
hkerwin@premierfundingservice.com
Kelly Black
kblack@premierfundingservice.com
Premier Media Service Inc.
(480) 649-8224